RU2000111537A - Apolipoprotein A-1 Agonists AND THEIR USE FOR TREATMENT OF DISEASES CONNECTED WITH DYSLIPIDEMIA - Google Patents
Apolipoprotein A-1 Agonists AND THEIR USE FOR TREATMENT OF DISEASES CONNECTED WITH DYSLIPIDEMIAInfo
- Publication number
- RU2000111537A RU2000111537A RU2000111537/04A RU2000111537A RU2000111537A RU 2000111537 A RU2000111537 A RU 2000111537A RU 2000111537/04 A RU2000111537/04 A RU 2000111537/04A RU 2000111537 A RU2000111537 A RU 2000111537A RU 2000111537 A RU2000111537 A RU 2000111537A
- Authority
- RU
- Russia
- Prior art keywords
- apoa
- represented
- agonist
- leucine
- peptide
- Prior art date
Links
- 102000005666 Apolipoprotein A-I Human genes 0.000 title claims 69
- 108010059886 Apolipoprotein A-I Proteins 0.000 title claims 69
- 239000000556 agonist Substances 0.000 title claims 66
- 206010058108 Dyslipidaemia Diseases 0.000 title claims 9
- 206010061227 Lipid metabolism disease Diseases 0.000 title claims 9
- 201000010099 disease Diseases 0.000 title claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 44
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 29
- 239000004471 Glycine Substances 0.000 claims 22
- 235000001014 amino acid Nutrition 0.000 claims 18
- 150000002632 lipids Chemical class 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 13
- 239000004472 Lysine Substances 0.000 claims 13
- 229960005190 Phenylalanine Drugs 0.000 claims 13
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 12
- 229960003104 Ornithine Drugs 0.000 claims 12
- 229960001230 Asparagine Drugs 0.000 claims 10
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 10
- 235000009582 asparagine Nutrition 0.000 claims 10
- 229960005261 Aspartic Acid Drugs 0.000 claims 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 9
- 235000003704 aspartic acid Nutrition 0.000 claims 9
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229960002989 Glutamic Acid Drugs 0.000 claims 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 235000013922 glutamic acid Nutrition 0.000 claims 7
- 239000004220 glutamic acid Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 102100005974 LCAT Human genes 0.000 claims 4
- 101700074758 LCAT Proteins 0.000 claims 4
- -1 aliphatic amino acid Chemical class 0.000 claims 4
- 230000001588 bifunctional Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 102000018619 Apolipoproteins A Human genes 0.000 claims 2
- 108010027004 Apolipoproteins A Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 230000002378 acidificating Effects 0.000 claims 2
- 230000003213 activating Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002209 hydrophobic Effects 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 1
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
Images
Claims (56)
(i) пептид, содержащий от 15 до 29 аминокислотных остатков пептид или пептидный аналог, который образует амфипатическую α-спираль в присутствие липидов и который характеризуется следующей формулой (I)
Z1-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-Z2, или его фармацевтически приемлемая соль,
где X1 представлен пролином (Р), аланином (А), глицином (G), глутамином (Q), аспарагином (N), аспарагиновой кислотой (D) или D-пролином (р);
Х2 представлен алифатической аминокислотой;
Х3 представлен лейцином (L) или фенилаланином (F);
Х4 представлен кислой аминокислотой;
Х5 представлен лейцином (L) или фенилаланином (F);
Х6 представлен лейцином (L) или фенилаланином (F);
Х7 представлен гидрофильной аминокислотой;
X8 представлен кислой или основной аминокислотой;
Х9 представлен лейцином (L) или глицином (G) ;
Х10 представлен лейцином (L), триптофаном (W) или глицином (G);
Х11 представлен гидрофильной аминокислотой;
X12 представлен гидрофильной аминокислотой;
Х13 представлен глицином (G) или алифатической аминокислотой;
X14 представлен лейцином (L), триптофаном (W), глицином (G) или Nal;
X15 представлен гидрофильной аминокислотой;
X16 представлен гидрофобной аминокислотой;
X17 представлен гидрофобной аминокислотой;
Х18 представлен основной аминокислотой, глутамином (Q) или аспарагином (N);
X19 представлен основной аминокислотой, глутамином (Q) или аспарагином (N);
Х20 представлен основной аминокислотой;
X21 представлен алифатической аминокислотой;
Х22 представлен основной аминокислотой;
Х23 отсутствует или представлен основной аминокислотой;
Z1 представлен H2N- или RC(O)NH-;
Z2 представлен -C(O)NRR, -С(О)OR или -С(О)ОН, или соответствующей солью;
каждый R независимо друг от друга представлен -Н, C1-6-алкилом, C1-6-алкенилом, C1-6-алкинилом, С5-20-арилом, С6-26-арилом, 5-20-атомным гетероарилом, 6-26-атомным алкгетероарилом или 1-7-аминокислотным пептидом или пептидным аналогом;
каждый знак "-" между остатками Хn независимо друг от друга обозначает амидную связь, замещенную амидную связь, изостер амида или миметик амида; или
(ii) делегированную форму формулы (I), в которой по крайней мере одна и вплоть до восьми остатков из X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21 и X22 делегированы; или
(iii) измененную форму формулы (I), в которой по крайней мере одна и вплоть до восьми остатков из X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22 и Х23 по консервативному типу заменены на другие аминокислотные остатки.1. ApoA-I agonist, including:
(i) a peptide containing from 15 to 29 amino acid residues a peptide or peptide analogue that forms an amphipathic α-helix in the presence of lipids and which is characterized by the following formula (I)
Z 1 -X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17 -X 18 -X 19 -X 20 -X 21 -X 22 -X 23 -Z 2 , or a pharmaceutically acceptable salt thereof,
where X 1 is represented by proline (P), alanine (A), glycine (G), glutamine (Q), asparagine (N), aspartic acid (D) or D-proline (p);
X 2 is an aliphatic amino acid;
X 3 is represented by leucine (L) or phenylalanine (F);
X 4 is an acidic amino acid;
X 5 is represented by leucine (L) or phenylalanine (F);
X 6 is represented by leucine (L) or phenylalanine (F);
X 7 is a hydrophilic amino acid;
X 8 is an acidic or basic amino acid;
X 9 is represented by leucine (L) or glycine (G);
X 10 is represented by leucine (L), tryptophan (W) or glycine (G);
X 11 is a hydrophilic amino acid;
X 12 is a hydrophilic amino acid;
X 13 is glycine (G) or an aliphatic amino acid;
X 14 is represented by leucine (L), tryptophan (W), glycine (G) or Nal;
X 15 is a hydrophilic amino acid;
X 16 is a hydrophobic amino acid;
X 17 is a hydrophobic amino acid;
X 18 is represented by a basic amino acid, glutamine (Q) or asparagine (N);
X 19 is represented by a basic amino acid, glutamine (Q) or asparagine (N);
X 20 is represented by a basic amino acid;
X 21 is an aliphatic amino acid;
X 22 is represented by a basic amino acid;
X 23 is absent or represented by a basic amino acid;
Z 1 is H 2 N- or RC (O) NH-;
Z 2 is —C (O) NRR, —C (O) OR or —C (O) OH, or the corresponding salt;
each R is independently represented by —H, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 5-20 aryl, C 6-26 aryl, 5-20 atom heteroaryl, 6-26-atom alkheteroaryl or 1-7-amino acid peptide or peptide analogue;
each “-” between the residues X n independently of each other denotes an amide bond, a substituted amide bond, an amide isoster or amide mimetic; or
(ii) a delegated form of formula (I) in which at least one and up to eight residues from X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 and X 22 delegated; or
(iii) an altered form of formula (I) in which at least one and up to eight residues of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 21 , X 22 and X 23 are conservatively replaced with other amino acid residues.
и ацилированные по N-концу и (или) амидированные по С-концу, или этерифицированные их формы, при том, что Х обозначает Aib, Z обозначает Nal, a O обозначает орнитин.19. ApoA-I agonist according to claim 1, which is selected from the group including (see graphic part),
and N-acylated and / or C-amidated or esterified forms thereof, with X being Aib, Z being Nal, and O being ornithine.
HH[LLm-HH] nLLm-HH (II),
или его фармацевтически приемлемая соль,
где каждый показатель m независимо друг от друга является целым числом от 0 до 1;
n является целым числом от 0 до 10;
каждый "НН" независимо представляет пептид или пептидный аналог по п. 1;
каждый "LL" независимо представляет бифункциональный линкер; и
каждый знак "-" независимо обозначает ковалентную связь.20. ApoA-I multimeric agonist that exhibits at least 38% activation activity of the LCAT enzyme compared to human ApoA-I and which is characterized by formula II
HH [LL m -HH] n LL m -HH (II),
or a pharmaceutically acceptable salt thereof,
where each indicator m independently from each other is an integer from 0 to 1;
n is an integer from 0 to 10;
each "HH" independently represents a peptide or peptide analogue according to claim 1;
each "LL" independently represents a bifunctional linker; and
each “-” sign independently indicates a covalent bond.
X-Nya-X(ya-1)-(Nyb-X(yb-1))p, (III)
или его фармацевтически приемлемая соль,
где каждый Х независимо представлен НН[LLm-HH] nLLm-HH;
каждый НН независимо представлен базовым пептидом формулы (I) или его аналогом, или мутированным, укороченным, делегированным по внутреннему положению или достроенным вариантом в соответствии с описанным в данном тексте;
каждый LL независимо представлен бифункциональным линкером;
каждый m независимо является целым числом от 0 до 1;
каждый n независимо является целым числом от 0 до 8;
Nya и Nyb независимо друг от друга многофункциональной связывающей составляющей, где yа и yb представляют число функциональных групп, соответственно, в Nya и Nyb;
каждый yа иди уb независимо является целым числом от 3 до 8;
р является целым числом от 0 до 7; и
каждый знак "-" независимо обозначает ковалентную связь.21. ApoA-I multimeric agonist that exhibits at least 38% activity for activating the LCAT enzyme compared to human ApoA-I and which is characterized by the formula (III):
XN ya -X (ya-1) - (N yb -X (yb-1) ) p , (III)
or a pharmaceutically acceptable salt thereof,
where each X is independently represented by HH [LL m -HH] n LL m -HH;
each HH is independently represented by a basic peptide of formula (I) or its analogue, or mutated, shortened, delegated in internal position or completed version in accordance with what is described in this text;
each LL is independently represented by a bifunctional linker;
each m is independently an integer from 0 to 1;
each n is independently an integer from 0 to 8;
N ya and N yb are independently of each other a multifunctional binding component, where y a and y b represent the number of functional groups, respectively, in N ya and N yb ;
each y a go y b is independently an integer from 3 to 8;
p is an integer from 0 to 7; and
each “-” sign independently indicates a covalent bond.
или
или его фармацевтически приемлемая соль,
где каждый Х независимо представлен HH[LLm-HH] nLLm-HH;
каждый НН независимо представлен пептидом или пептидным аналогом по п. 1;
каждый LL независимо представлен бифункциональным линкером;
каждый n независимо является целым числом от 0 до 1;
каждый m независимо является целым числом от 0 до 8;
R1 является -OR или -NRR;
каждый R независимо представлен -Н, C1-6-алкилом, C1-6-алкенилом, C1-6-алкинилом, С5-20-арилом, С6-26-алкарилом, 5-20-атомным гетероарилом или 6-26-атомным алкгетероарилом.22. ApoA-I multimeric agonist that exhibits at least 38% LCAT activation activity compared to human ApoA-I and which is characterized by formula (IV) or (V)
or
or a pharmaceutically acceptable salt thereof,
where each X is independently represented by HH [LL m -HH] n LL m -HH;
each HH is independently represented by a peptide or peptide analogue according to claim 1;
each LL is independently represented by a bifunctional linker;
each n is independently an integer from 0 to 1;
each m is independently an integer from 0 to 8;
R 1 is —OR or —NRR;
each R is independently represented by —H, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 5-20 aryl, C 6-26 alkaryl, 5-20 atom heteroaryl, or 6 26 atomic alkheteroaryl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/940,095 | 1997-09-29 | ||
US08/940,095 US6004925A (en) | 1997-09-29 | 1997-09-29 | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000111537A true RU2000111537A (en) | 2002-04-27 |
RU2215747C2 RU2215747C2 (en) | 2003-11-10 |
Family
ID=25474217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000111537/04A RU2215747C2 (en) | 1997-09-29 | 1998-09-28 | Agonists of apolipoprotein a-i and their using for treatment of dyslipidemia-mediated diseases |
Country Status (20)
Country | Link |
---|---|
US (11) | US6004925A (en) |
EP (2) | EP1854471B1 (en) |
JP (1) | JP2001518282A (en) |
KR (1) | KR100650929B1 (en) |
CN (1) | CN1247254C (en) |
AT (2) | ATE383865T1 (en) |
AU (3) | AU746090B2 (en) |
CA (1) | CA2304805A1 (en) |
DE (2) | DE69839014T2 (en) |
DK (2) | DK1019073T3 (en) |
ES (2) | ES2331808T3 (en) |
HU (1) | HUP0002381A3 (en) |
IL (1) | IL135318A0 (en) |
NO (1) | NO20001599L (en) |
NZ (1) | NZ503717A (en) |
PL (1) | PL196675B1 (en) |
PT (1) | PT1019073E (en) |
RU (1) | RU2215747C2 (en) |
UA (1) | UA71553C2 (en) |
WO (1) | WO1999016459A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2604132C2 (en) * | 2011-11-30 | 2016-12-10 | Дэунг Фармасьютикл Ко., Лтд. | Pharmaceutical composition for preventing or treating hypertriglyceridemia or diseases, caused by hypertriglyceridemia |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
WO2000059855A1 (en) | 1999-04-01 | 2000-10-12 | Esperion Therapeutics, Inc. | Ether compounds, compositions, and uses thereof |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
US7407662B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
JP4344136B2 (en) * | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | Apolipoprotein analog |
DK1335938T3 (en) * | 2000-11-10 | 2010-12-13 | Hoffmann La Roche | Apolipoprotein construct |
WO2003000372A2 (en) * | 2001-06-25 | 2003-01-03 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
WO2003026588A2 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Methods and apparatus for extrusion of vesicles at high pressure |
CA2460787A1 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
WO2003049685A2 (en) * | 2001-12-07 | 2003-06-19 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
AU2003234625A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
AU2003239489A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
NL1020962C2 (en) * | 2002-06-28 | 2003-12-30 | Tno | Therapy and prognosis / monitoring for sepsis and septic shock. |
WO2004004774A2 (en) * | 2002-07-03 | 2004-01-15 | Esperion Therapeutics, Inc. | Compositions comprising panthetine for the treatment of dyslipidemia |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
NZ539672A (en) * | 2002-10-24 | 2006-09-29 | Enos Pharmaceuticals Inc | Sustained release L-arginine-formulations and methods of manufacture and use |
PT2404890T (en) * | 2003-01-23 | 2017-10-23 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for cholesterol management and related uses |
DK2368565T3 (en) | 2003-07-03 | 2015-09-28 | Hdl Therapeutics Inc | Enrichment of pre-beta lipoproteins, high density |
US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
AU2004299486B2 (en) * | 2003-12-15 | 2011-05-19 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
JP2007517550A (en) * | 2004-01-02 | 2007-07-05 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Medical device coated with high density lipoprotein |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US8926958B2 (en) * | 2004-04-06 | 2015-01-06 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano |
EP1602931A1 (en) * | 2004-06-03 | 2005-12-07 | Universiteit Leiden | SR-A antagonists |
UY28952A1 (en) * | 2004-06-09 | 2006-01-31 | Avanir Pharmaceuticals | CHOLESTEROL INVERSE TRANSPORTATION MEDIATORS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA |
AR049216A1 (en) * | 2004-06-09 | 2006-07-05 | Avanir Pharmaceuticals | HETEROCICLIC DERIVATIVES AS MEDIATORS OF INVERSE TRANSPORTATION OF CHOLESTEROL FOR THE TREATMENT OF HYPERLIPIDEMIA AND RELATED CARDIOVASCULAR DISEASES |
UY28951A1 (en) * | 2004-06-09 | 2006-01-31 | Avanir Pharmaceuticals | SMALL MOLECULES FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES |
EP1800126B1 (en) * | 2004-09-08 | 2014-12-17 | The United States of America as represented by the Secretary of Health and Human Services, NIH | Compositions and methods for the detection of hiv-1/hiv-2 infection |
US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
EP2218736A1 (en) | 2004-10-15 | 2010-08-18 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Implant coated with multi-domain amphipathic helical peptides and methods of their use |
US7579319B2 (en) | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
US7759315B2 (en) | 2005-03-09 | 2010-07-20 | Csl Behring Ag | Treatment of inflammatory conditions of the intestine |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
EP2269623A1 (en) * | 2005-04-29 | 2011-01-05 | The Regents of The University of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
WO2006125304A1 (en) * | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Pharmaceutical compositions for treating or preventing coronary artery disease |
GR1005428B (en) * | 2005-05-27 | 2007-02-01 | Χαραλαμπος Αλεξοπουλος | Synthetic lipopeptides with antiatherogenic action that hinder tha oxidation of low density lipoprotein (ldl) and inhibit the deactivation of the enzyme of the paf-acetylhydrolase (paf-ah) |
NZ565955A (en) | 2005-08-22 | 2011-08-26 | Melior Pharmaceuticals I Inc | Methods and formulations for modulating lyn kinase activity and treating related disorders |
GB0602598D0 (en) * | 2006-02-09 | 2006-03-22 | Cheesmond David | Quick change front F2 sidecar |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
TW200744627A (en) * | 2006-02-21 | 2007-12-16 | Pfizer Prod Inc | Methods for the treatment of macular degeneration and related eye conditions |
MX2008015337A (en) * | 2006-06-01 | 2009-11-26 | Inst Cardiologie Montreal | Method and compound for the treatment of valvular stenosis. |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
US20080199398A1 (en) * | 2006-06-16 | 2008-08-21 | Brewer H Bryan | Novel Peptides That Promote Lipid Efflux |
WO2008021088A2 (en) | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
MX2009008135A (en) * | 2007-01-31 | 2009-08-12 | Nutrition 21 Inc | Use of chromium histidinate for treatment of cardiometabolic disorders. |
EP2120581A4 (en) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | Methods of identifying activators of lyn kinase |
EP1964571B1 (en) | 2007-03-01 | 2012-05-02 | CSL Limited | Treatment of endothelial dysfunction in diabetic patients |
CA3013149C (en) | 2007-03-13 | 2021-12-07 | Jds Therapeutics, Llc | Methods and compositions for the sustained release of chromium |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
NZ579288A (en) * | 2007-07-23 | 2012-06-29 | Melior Discovery Inc | Methods of activating irs-1 and akt |
JP2010535245A (en) * | 2007-07-31 | 2010-11-18 | バーンハム インスティテュート フォー メディカル リサーチ | Bidentate compounds as kinase inhibitors |
US8431529B2 (en) * | 2007-07-31 | 2013-04-30 | Sanford-Burnham Medical Research Institute | Bi-dentate compounds as kinase inhibitors |
WO2009032693A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
WO2009032702A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
AU2008296444A1 (en) * | 2007-08-29 | 2009-03-12 | The Regents Of The University Of California | Salicylanilide modified peptides for use as oral therapeutics |
US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
US8936787B2 (en) * | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
KR101967417B1 (en) | 2008-11-10 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | Novel lipids and compositions for the delivery of therapeutics |
WO2010083611A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
AU2010213568B2 (en) | 2009-02-16 | 2014-11-20 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I Mimics |
AU2010223967B2 (en) | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
WO2010135663A2 (en) | 2009-05-21 | 2010-11-25 | The United States Of America , As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the detection of hiv-1/hiv-2 infection |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
KR101766408B1 (en) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | Improved lipid formulation |
EP2464336A4 (en) | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
WO2011040654A1 (en) * | 2009-09-30 | 2011-04-07 | 서울대학교산학협력단 | Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same |
US10525152B2 (en) | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
ES2749426T3 (en) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Nucleic Acid Administration Methods and Compositions |
EP2517013A4 (en) * | 2009-12-23 | 2013-07-17 | Artery Therapeutics Inc | Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
DK2575764T3 (en) | 2010-06-03 | 2017-08-07 | Alnylam Pharmaceuticals Inc | BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
US8728749B2 (en) | 2010-12-31 | 2014-05-20 | Bruce J. Auerbach | Detection of LCAT activity |
DK3202760T3 (en) | 2011-01-11 | 2019-11-25 | Alnylam Pharmaceuticals Inc | PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY |
PT2673296T (en) | 2011-02-07 | 2019-01-31 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and manufacturing and uses thereof |
EP2680861B1 (en) | 2011-03-01 | 2022-05-04 | Nutrition 21, LLC | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
KR102069395B1 (en) | 2011-12-12 | 2020-01-22 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Treatment of type i and type ii diabetes |
AU2014228815B2 (en) | 2013-03-15 | 2019-04-18 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
EP3137899A2 (en) | 2014-05-02 | 2017-03-08 | Cerenis Therapeutics Holding SA | Hdl therapy markers |
US10220046B2 (en) | 2014-07-14 | 2019-03-05 | The Regents Of The University Of Michigan | Compositions and methods for disease treatment using nanoparticle delivered compounds |
MX2017001432A (en) | 2014-07-31 | 2017-05-09 | Uab Res Found | Apoe mimetic peptides and higher potency to clear plasma cholesterol. |
SG11201707497UA (en) | 2015-03-13 | 2017-10-30 | Esperion Therapeutics Inc | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
MA41793A (en) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK |
AU2016238290B9 (en) | 2015-03-25 | 2019-06-13 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
WO2016154542A2 (en) * | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
JP2018528257A (en) | 2015-07-10 | 2018-09-27 | ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーPeptinovo Biopharma, LLC | Formulations for improving the efficacy of hydrophobic drugs |
AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
BR112019001459A2 (en) | 2016-07-27 | 2019-05-07 | Hartis-Pharma Sa | combination, pharmaceutical composition, and method of preventing and / or treating a disease or disorder. |
FR3061715B1 (en) * | 2017-01-12 | 2021-07-30 | Institut National Univ Jean Francois Champollion | PEPTIDE IMMUNOMODULATOR |
US11027052B2 (en) | 2017-11-22 | 2021-06-08 | HDL Therapuetics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
AU2018250795B2 (en) | 2017-04-10 | 2022-02-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatment of adipocytes |
EP3668600A1 (en) | 2017-08-10 | 2020-06-24 | Abionyx Pharma SA | Cargomers |
US11400082B2 (en) | 2017-10-30 | 2022-08-02 | Montréal Heart Institute | Methods of treating elevated plasma cholesterol |
CA3087207A1 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
CN110294791B (en) * | 2019-06-13 | 2023-02-21 | 倪京满 | Anti-atherosclerotic peptide analogue with cholesterol efflux activity and application thereof |
EP3986860A1 (en) | 2019-06-21 | 2022-04-27 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
IL297336A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
MX2023003877A (en) | 2020-10-01 | 2023-04-18 | Abionyx Pharma Sa | Compositions comprising lipid binding protein-based complexes for use for treating eye diseases. |
AU2022258815A1 (en) | 2021-04-15 | 2023-10-19 | Abionyx Pharma Sa | Use of lipid binding protein-based complexes in organ preservation solutions |
WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
WO2023194798A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
WO2023237935A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH621479A5 (en) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
DE3241102A1 (en) * | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | IMIDAZOLYLALKYLTHIENYL TETRAHYDROPYRIDAZINE AND METHOD FOR THE PRODUCTION THEREOF |
US4643988A (en) * | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
ATE171192T1 (en) * | 1992-06-12 | 1998-10-15 | Innogenetics Nv | PEPTIDES AND PROTEINS, METHOD FOR THE PRODUCTION THEREOF AND THE USE AS CHOLESTEROL ACCEPTORS |
US5674855A (en) * | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
US5344822A (en) * | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
SE9203753D0 (en) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M |
FR2723741A1 (en) * | 1994-08-16 | 1996-02-23 | Fournier Sca Lab | PEPTIDES INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN AND THEIR USE IN THERAPEUTICS |
FR2734568B1 (en) * | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | NEW VARIANTS OF APOLIPOPROTEIN |
AU710061B2 (en) | 1996-03-29 | 1999-09-09 | Dario Boffelli | Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
GB9609702D0 (en) | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
WO1998029736A1 (en) * | 1996-12-31 | 1998-07-09 | Genometrix Incorporated | Multiplexed molecular analysis apparatus and method |
US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
US6977155B2 (en) * | 2000-08-10 | 2005-12-20 | Corning Incorporated | Arrays of biological membranes and methods and use thereof |
-
1997
- 1997-09-29 US US08/940,095 patent/US6004925A/en not_active Expired - Fee Related
-
1998
- 1998-09-28 EP EP06018390A patent/EP1854471B1/en not_active Expired - Lifetime
- 1998-09-28 AT AT98951978T patent/ATE383865T1/en not_active IP Right Cessation
- 1998-09-28 EP EP98951978A patent/EP1019073B1/en not_active Expired - Lifetime
- 1998-09-28 AU AU97790/98A patent/AU746090B2/en not_active Ceased
- 1998-09-28 IL IL13531898A patent/IL135318A0/en unknown
- 1998-09-28 DE DE69839014T patent/DE69839014T2/en not_active Expired - Lifetime
- 1998-09-28 ES ES06018390T patent/ES2331808T3/en not_active Expired - Lifetime
- 1998-09-28 RU RU2000111537/04A patent/RU2215747C2/en not_active IP Right Cessation
- 1998-09-28 NZ NZ503717A patent/NZ503717A/en unknown
- 1998-09-28 PT PT98951978T patent/PT1019073E/en unknown
- 1998-09-28 CA CA002304805A patent/CA2304805A1/en not_active Abandoned
- 1998-09-28 DK DK98951978T patent/DK1019073T3/en active
- 1998-09-28 ES ES98951978T patent/ES2300125T3/en not_active Expired - Lifetime
- 1998-09-28 CN CNB988116677A patent/CN1247254C/en not_active Expired - Fee Related
- 1998-09-28 WO PCT/US1998/020327 patent/WO1999016459A1/en active IP Right Grant
- 1998-09-28 PL PL339629A patent/PL196675B1/en not_active IP Right Cessation
- 1998-09-28 DE DE69841030T patent/DE69841030D1/en not_active Expired - Lifetime
- 1998-09-28 UA UA2000042495A patent/UA71553C2/en unknown
- 1998-09-28 JP JP2000513593A patent/JP2001518282A/en not_active Withdrawn
- 1998-09-28 DK DK06018390T patent/DK1854471T3/en active
- 1998-09-28 HU HU0002381A patent/HUP0002381A3/en unknown
- 1998-09-28 KR KR1020007003402A patent/KR100650929B1/en not_active IP Right Cessation
- 1998-09-28 AT AT06018390T patent/ATE437648T1/en not_active IP Right Cessation
-
1999
- 1999-12-01 US US09/453,826 patent/US6630450B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,833 patent/US6602854B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,840 patent/US6716816B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,841 patent/US6573239B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,605 patent/US6329341B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,834 patent/US6753313B1/en not_active Expired - Fee Related
- 1999-12-01 US US09/453,838 patent/US6376464B1/en not_active Expired - Fee Related
-
2000
- 2000-03-28 NO NO20001599A patent/NO20001599L/en not_active Application Discontinuation
-
2002
- 2002-03-15 US US10/099,836 patent/US7189689B2/en not_active Expired - Fee Related
- 2002-07-17 AU AU2002300785A patent/AU2002300785B2/en not_active Ceased
-
2003
- 2003-11-17 US US10/715,895 patent/US7307058B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/802,080 patent/US7312190B2/en not_active Expired - Fee Related
-
2005
- 2005-05-10 AU AU2005201985A patent/AU2005201985B2/en not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2604132C2 (en) * | 2011-11-30 | 2016-12-10 | Дэунг Фармасьютикл Ко., Лтд. | Pharmaceutical composition for preventing or treating hypertriglyceridemia or diseases, caused by hypertriglyceridemia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2215747C2 (en) | Agonists of apolipoprotein a-i and their using for treatment of dyslipidemia-mediated diseases | |
RU2000111537A (en) | Apolipoprotein A-1 Agonists AND THEIR USE FOR TREATMENT OF DISEASES CONNECTED WITH DYSLIPIDEMIA | |
RU2219941C2 (en) | Agonists of apolipoprotein a-1 and their application for treatment of dyslipidemia-associated diseases | |
RU2000111540A (en) | APOLIPOPROTEIN A-1 AGONISTS AND THEIR APPLICATION FOR TREATMENT OF DISEASES CONNECTED WITH DYSLIPIDEMIA | |
RU2214831C2 (en) | Agonists of apolipoprotein a-1 and their using in treatment of dyslipidemic disorders | |
RU2000111534A (en) | APONIPOPROTEIN A-1 AGONISTS AND THEIR APPLICATION IN THE TREATMENT OF DYSLIPIDEMIC DISORDERS | |
RU2000111526A (en) | GENOTHERAPEUTIC METHODS FOR INTRODUCING APOLIPOPROTEIN A-I AGONISTS AND THEIR APPLICATION FOR TREATMENT OF DYSLIPIDEMIC DISORDERS | |
CN109640953B (en) | Injectable solutions comprising copolymerized amino acids with carboxylate charge and hydrophobic groups | |
RU2194054C2 (en) | Synthetic analogs of il-10 | |
DE60119145D1 (en) | AN ANTIGEN AND AN ADJUVANS PEPTIDE CONTAINING VACCINE COMPOSITION | |
IL95118A0 (en) | Polypeptide derivatives,their preparation and pharmaceutical compositions containing them | |
ES2163444T3 (en) | COMPOSITIONS AND METHODS FOR THE ORAL ADMINISTRATION OF PHARMACOS. | |
RU2223970C2 (en) | Obesity treatment | |
DE69024230D1 (en) | AMINO ACIDS, PEPTIDES OR DERIVATIVES BONDED TO FATS | |
WO2003035695A3 (en) | Agents that activate or inhibit toll-like receptor 9 | |
JP2004535461A5 (en) | ||
JP3786533B2 (en) | Peptide and osteogenesis promoter | |
KR910002899A (en) | Blood Regulatory Peptides | |
RU2205186C2 (en) | Labeled analogues of glutamine and lysine | |
JP2003073400A (en) | New peptide having osteogenic activity and osteogenesis stimulator prepared by immobilizing the same | |
Koyack et al. | Design and synthesis of β-peptides with biological activity | |
WO2001018031A3 (en) | Peptides and pharmaceutical compositions comprising same | |
KR940021074A (en) | Pharmaceutical composition consisting of VIP, or analogs, derivatives or fragments thereof | |
JPH07509714A (en) | Peptide pulmonary surfactants and therapeutic combinations | |
RU93057732A (en) | N - // 4,5-DIOXI- and 4,5,8-TRIHYDROXI-9,10-DIHYDRO-9,10-DIOXO-2-ANTHRACENIL (CARBONYL) - AMINO ACIDS, USEFUL FOR THE TREATMENT OF BONUS-STRONG DISEASES |